Respiratory microbiome and epithelial interactions shape immunity in the lungs

Summary

The airway epithelium represents a physical barrier to the external environment acting as the first line of defence against potentially harmful environmental stimuli including microbes and allergens. However, lung epithelial cells are increasingly recognized as active effectors of microbial defence, contributing to both innate and adaptive immune function in the lower respiratory tract. These cells express an ample repertoire of pattern recognition receptors with specificity for conserved microbial and host motifs. Modern molecular techniques have uncovered the complexity of the lower respiratory tract microbiome. The interaction between the microbiota and the airway epithelium is key to understanding how stable immune homeostasis is maintained. Loss of epithelial integrity following exposure to infection can result in the onset of inflammation in susceptible individuals and may culminate in lung disease. Here we discuss the current knowledge regarding the molecular and cellular mechanisms by which the pulmonary epithelium interacts with the lung microbiome in shaping immunity in the lung. Specifically, we focus on the interactions between the lung microbiome and the cells of the conducting airways in modulating immune cell regulation, and how defects in barrier structure and function may culminate in lung disease. Understanding these interactions is fundamental in the search for more effective therapies for respiratory diseases.

Keywords: immunity; lungs; mucosal immunology; respiratory epithelium; respiratory microbiome.

The epithelial barrier

The human respiratory tract is the main portal of entry for the continuous immigration and elimination of a vast array of airborne microorganisms and particles, including viruses, bacteria and fungi. The lungs are continually exposed to a multitude of microorganisms, some of which are able to persist and colonize the respiratory

Abbreviations: AEC1, alveolar epithelial type 1 cells; AEC2, alveolar epithelial type 2 cells; BAL, bronchoalveolar lavage; CF, cystic fibrosis; CLRs, C-type lectin receptors; COPD, chronic obstructive pulmonary disease; DKK, Dikkopf; EGFR, epidermal growth factor receptor; GORD, gastro-oesophageal reflux disease; HHV, human herpes virus; ICAM-1, intracellular adhesion molecule 1; IPF, idiopathic pulmonary fibrosis; KRM, Kreme; Man-6-P, mannose-6-phosphate; NLRs, NOD-like receptors; NOD, nucleotide-binding and oligomerization domain; PAF, platelet-activating factor; PAMPs, pathogen-associated molecular patterns; PARs, protease-activated receptors; PRR, pattern recognition receptors; RLRs, retinoic acid-inducible gene-I-like receptors; RSV, respiratory syncytial virus; SCFA, short-chain fatty acid; TARC, thymus- and activation-regulated chemokine; TEER, transepithelial electrical resistance; Th2, T helper 2; TIR, toll/IL-1 receptor; TLRs, toll-like receptors; TRIF, TIR-domain-containing adapter-inducing interferon-β; TSLP, thymic stromal lymphopoietin

© 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology, 160, 171–182 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
tract. These microbes that reside in the lower airways constitute the lung microbiome, which is distinct in composition from the microbiota observed in the oral and nasal cavities. The surface of the lungs presents a continuous layer of epithelial cells that constitute a physical and biological barrier for inhaled substances and pathogens. The specialized respiratory epithelium is required for maintenance of immune homeostasis, and epithelial dysfunction is involved in the development of many inflammatory disorders of the airways and lungs. The respiratory tract is a complex organ system, and its primary function is the exchange of oxygen and carbon dioxide. It is divided into the upper respiratory tract including the nasal cavity, pharynx, larynx, and the lower respiratory tract that comprises the conducting airways (trachea and bronchi), the small airways (bronchioles) and the respiratory zone (the alveoli). The adult human airways have a surface area of approximately 70 m², which harbours a vast range of bacterial communities, with the highest bacterial load observed in the upper respiratory tract. The respiratory tract spans different anatomical sites, and the types of epithelial cells that comprise these sites are varied both in composition and in structure, reflecting the distinct functions of the airway epithelial cells lining the conducting airways and the alveolar regions of the lungs (Fig. 1).

In the lower respiratory tract, the respiratory epithelium provides a highly effective barrier acting as the first line of defence against potentially harmful environmental stimuli including microbes and allergens. The pseudostriatified epithelium of the conducting airways is primarily comprised of multi-ciliated cells, mucus-secreting goblet cells, neuroendocrine cells and basal cells, which secrete surfactant. It constitutes the first site of interaction with inhaled environmental compounds, and is designed to facilitate effective mucociliary clearance of particles and microbes. Multi-ciliated cells have cilia on the apical surface that beat co-ordinately to shuttle inhaled particulates and mucus out of the airways whilst goblet and secretory cells trap inhaled particulates and microorganisms. Basal cells are progenitor cells that act as resident stem cells for the trachea and proximal airways. These cells are capable of self-renewal as well as repopulating the pseudostratified epithelium during homeostasis and after injury. The tracheal region and large airways harbour stromal cells such as interstitial fibroblasts that aid in the regulation of the regenerative response of the airway epithelium after injury. In contrast, the alveolar surfaces in the peripheral lung are lined by flat alveolar epithelial type 1 cells (AEC1) that form a continuous cell layer and are specialized in gas exchange, while cuboidal alveolar epithelial type 2 cells (AEC2) act as progenitor cells and secrete pulmonary surfactant, which reduces surface tension in order to prevent alveolar collapse during respiration. A common feature shared by these cell types is the presence of intracellular tight junctions that are localized at the apical surface, and are pivotal for epithelial adhesion and barrier function. These tight junctions ensure the cells adhere together to form a regulated impermeable barrier. This intracellular adhesion complex consists of interconnections of proteins and receptors including, zonular occluden (ZO)-1, -2 and -3, occludins, claudins, and transmembrane junctional adhesion molecules. Tight junctions control paracellular dispersion, and immediately below them are the adherens junctions, composed of β-catenin and E-cadherin, which mechanically connect the adjacent cells and initiate proliferation and differentiation. The presence and function of these complexes can be influenced by cellular differentiation, exposure to a range of stimuli, such as allergens and pollutants, and may be altered in disease conditions, contributing to immunopathology.

The lung microbiota in health and disease

The long-held, but incorrect, theory of sterility of the lung outside of clinical infection means historically little work has evaluated the role of the lung microbiota in chronic lung disease. Advances in high-throughput molecular sequencing technologies have debunked this notion, demonstrating that the epithelial surfaces of the human respiratory tract are colonized by a complex and dynamic microbiota, termed the 'lung microbiome', which plays a role both in health and disease. The most commonly used approach to the study of bacterial communities exploits high-throughput sequencing of amplicons of the 16S rRNA gene, a highly conserved locus in the bacterial genome that contains specific variable regions that can be used for phylogenetic classification. Sequencing studies have demonstrated stark differences in the lung microbiome between health and disease, and it is becoming increasingly apparent that the lung microbiome may not only contribute to explain the pathogenesis of these diseases, but also serve as a prognostic marker and therapeutic target.

In health, the lung microbiota has a low density but harbours a prominent diversity of interacting microbiota. The airway microbiota in healthy lungs is dominated by the Bacteroidetes, Firmicutes and Proteobacteria. Prominent genera in the lower airways include Prevotella, Veillonella and Streptococcus. The composition of the lung microbiome is determined by three factors: microbial immigration; microbial elimination; and the relative reproduction rates of its members. The main routes of microbial immigration to the lungs are inhalation of air-borne bacteria, direct dispersion along mucosal surfaces and microaspiration. The similarities in community composition between the oral and lung microbiota suggest that microaspiration is likely to be the dominant route of immigration. Microbial elimination is an active process that is achieved through mucociliary clearance, cough...
and host immune defences. The environmental conditions necessary for microbial growth within the respiratory tract (e.g. pH, temperature, nutrient availability, oxygen tension and activation of host inflammatory cells) are heterogeneous, and considerable regional variation can be observed in a single healthy lung. During lung disease, the balance between immigration and elimination is perturbed, leading to alterations in the lung microbiota, with bacteria exhibiting competitive advantages becoming predominant (Table 1). This overgrowth of bacterial species leads to a decrease in overall richness, and is associated with the progression of chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). Furthermore, these studies have linked microbial dysbiosis with an increased morbidity and mortality in a multitude of chronic respiratory diseases.

In addition to the bacterial component of the microbiome, there is evidence that other non-bacterial...
organisms, including viruses and fungi, may play an important role in health and disease. Emerging evidence suggests that the lung virome and mycobiome have a significant impact on clinical outcome of chronic respiratory diseases such as asthma, COPD, CF and IPF. It is also increasingly recognized that respiratory viruses are a major cause of acute exacerbations of chronic pulmonary diseases, and that the host response to viral infection is dysregulated in these diseases. For example, studies support a mechanistic role for viruses in the initiation and progression of IPF. The human herpes virus (HHV) family, which includes cytomegalovirus, Epstein–Barr virus, HHV-7 and HHV-8, has received considerable attention about the lung mycobiome compared with the bacterial microbiome, in recent years specific fungi have been identified in respiratory diseases. It has also been shown that commensal fungi can affect the immune system and also modulate bacterial communities, thus contributing to the restoration of the bacterial microbiome following antibiotic treatment. Although studies into the composition and function of lung viral and fungal communities are gaining momentum, research in this field is still in its infancy, and future mechanistic work is needed to yield novel insights into their role in the pathogenesis of pulmonary diseases.

**A homeostatic balance between the lung and its microbiota**

Airway epithelial cells are in continuous contact with the environment, and this interaction is a crucial factor in maintaining stable homeostasis. The three essential components that contribute to the barrier function of airway epithelium are: mucociliary escalators that trap and remove inhaled microbes and noxious stimuli from the airways; intracellular tight and adherens junctions that regulate epithelial paracellular permeability; and secreted antimicrobial peptides that kill inhaled pathogens. The physiological features of the respiratory tract are pivotal for maintaining a balance between the lung and its microbiota. The pulmonary epithelium is composed of distinct cell types and is not continuous from the upper respiratory tract to the alveoli. In the large airways, the submucosal gland harbours the mucus and serous cells that are responsible for the production of most airway mucus. Towards the bronchioles, goblet and club cells produce mucus, whereas in the alveoli AEC1 and AEC2 secrete pulmonary surfactant. Mucus is a gel composed mainly of water and glycosylated proteins, such as mucins. Although studies into the composition and function of lung viral and fungal communities are gaining momentum, research in this field is still in its infancy, and future mechanistic work is needed to yield novel insights into their role in the pathogenesis of pulmonary diseases.

### Table 1. Summary of studies illustrating changes in the respiratory microbiome that occur during chronic lung disease

| Disease | Taxonomic changes at the genus level | Sample type | Cohort size | [Ref.]
|---------|-----------------------------------|-------------|-------------|--------|
| Asthma  | Increased abundance of *Haemophilus* | Bronchoscopy | 11          | 16     |
|         | Increased abundance of *Haemophilus*, *Neisseria*, *Fusobacterium* and *Porphyromonas* | Bronchoscopy | 42          | 29     |
|         | Increased abundance of *Streptococcus* | Nasopharyngeal | 234        | 30     |
| COPD    | Increased abundance of *Lactobacillus* | Lung tissue  | 24          | 17     |
|         | Increased abundance of *Fusobacteria*, *Leptotrichia* and *Fusobacterium* | BAL         | 32          | 31     |
| CF      | Increased abundance of *Burkholderia*, *Streptococcus* and *Staphylococcus* | Sputum      | 23          | 25     |
|         | Increased abundance of *Pseudomonas*, *Staphylococcus*, *Stenotrophomonas* and *Achromobacter* | Sputum      | 17          | 32     |
|         | Increased abundance of *Staphylococcus*, *Streptococcus* and *Pseudomonas* | BAL         | 95          | 33     |
| IPF     | Increased abundance of *Haemophilus*, *Streptococcus*, *Neisseria* and *Veillonella* | BAL         | 65          | 19     |
|         | Increased abundance of *Staphylococcus* and *Streptococcus* | BAL         | 55          | 20     |
|         | Increased abundance of *Streptococcus*, *Prevotella*, *Veillonella*, *Haemophilus* and *Pseudomonas* | BAL         | 35          | 26     |

**BAL**, bronchoalveolar lavage; **CF**, cystic fibrosis; **COPD**, chronic obstructive pulmonary disease; **IPF**, idiopathic pulmonary fibrosis.

1 Changes in the microbiota in cases compared with controls.
a major ecological niche for the microbiota; it promotes healthy interactions between microorganisms and epithelial cells through the formation of a thin mobile layer that is supported by the periciliary layer covering the cilia. In health, the mucus layer provides an effective defence against epithelial injury; however, excessive mucus production is associated with increased susceptibility to viral infections, respiratory allergies, and contributes to obstruction in several respiratory diseases such as pneumonia, asthma, COPD and CF. This obstruction hinders the ability of the cilia to transport mucus out of the lungs, and favours the selection of certain pathogenic bacteria that thrive in mucus and establish themselves in this obstructed niche. Furthermore, microaspiration is commonly observed in chronic lung disease, and gastro-oesophageal reflux disease (GORD) has emerged as a frequent co-morbidity in chronic respiratory disorders. Although GORD is typically confined to the lower oesophagus, in some individuals it can be associated with pulmonary microaspiration of gastric contents. The occurrence of aspiration can lead to increased levels of bile acid in the lungs, which can favour the establishment of microbial biofilms, composed of microbial cells that form structured communities embedded in an extracellular matrix. Bacterial and fungal biofilms have emerged as a mechanism of virulence for opportunistic pathogens including Pseudomonas aeruginosa and staphylococcal species. A hallmark of biofilms is their remarkable antimicrobial tolerance, which allows them to persist in the host and evade the host immune system. Therefore, GORD-derived bile and subsequent biofilm growth on host tissue may contribute to chronic respiratory infection. In addition, direct seeding of bacteria from the intestinal microbiota into the airways may play a role in influencing the interaction between the epithelium and the microbiome.

The intracellular tight and adherens junctions provide fundamental adhesive contacts between neighbouring epithelial cells. Tight junctions are the main regulators of paracellular permeability, whereas the adherens junctions mechanically connect adjacent cells, and initiate the formation and maturation of cell–cell contacts. During disease, barrier function is impaired leading to increased epithelial permeability and pathogen entry. Upon infection, epithelial cells are able to respond by the release of humoral factors such as antimicrobial peptides that exert broad-spectrum antimicrobial activity, and a number of these are upregulated in response to the microbial dysbiosis seen in disease. Defensins are the most abundant antimicrobial peptides, and comprise defensin in neutrophils and β-defensin in epithelial cells. Human β-defensin 1, 2, 3 and 4 are largely expressed on airway epithelial cells and function in airway mucosal defence by targeting a wide range of respiratory pathogens. Their expression in airway epithelia may be constitutive or inducible by bacterial products or proinflammatory cytokines. Nutrient availability in each specific niche will also play a role in the maintenance and selection of the lung microbiota. Host compounds such as mucins, cytokines, defensins and lactoferrins are the nutrient source available for bacteria in the lungs. Microbial growth rates can also be influenced by changes in oxygen tension. Within the lungs there is significant regional variation in oxygen tension that can alter population dynamics by affecting bacterial proliferation. In chronic pulmonary diseases, an increased mucus production promotes bacterial growth and leads to the formation of zones with low oxygen concentration and high temperature favouring the selection and maintenance of particular bacteria. Collectively, these differences in the cellular function and the physiological characteristics of the lungs (e.g. temperature, mucus, pulmonary surfactant and oxygen tension) have a major impact on the establishment and persistence of the bacterial communities.

The airway epithelium as a sensor of microbial presence

The airway epithelium not only represents a structural barrier but is also integral for innate host defence. Airway epithelial cells express several pattern recognition receptors (PRRs), and secrete antimicrobial molecules and mucins that aid in the defence against invading pathogens. PRRs are germ-line encoded receptors that recognize conserved pathogen-associated molecular patterns (PAMPs) or cell damage-associated molecular patterns. These transmembrane receptors can be activated independently of the adaptive immune response and are classified into four families: the toll-like receptors (TLRs), the cytoplasmic proteins retinoic acid-inducible gene-I-like receptors (RLRs), the NOD-like receptors (NLRs) and the C-type lectin receptors (CLRs).

To date, 10 (TLR1–TLR10) have been identified in the human genome, and are characterized by N-terminal leucine-rich repeats, a transmembrane region and a cytoplasmic Toll/IL-1 receptor (TIR) homology domain that mediates signalling via MyD88 and TIR-domain-containing adapter-inducing interferon-β (TRIF). Toll-like receptors play an important role in pathogen recognition and innate immunity. The main function of TLRs in mammals is to recognize distinct PAMPs, including components of microbial cell walls (TLR1, TLR2, TLR4 and TLR6), flagellin (TLR5), single- or double-stranded viral RNA (TLR3, TLR7 and TLR8) or CpG-containing DNA (TLR9). The TLR3, 7, 8 and 9 are specifically localized in endosomes and detect pathogen nucleic acids following endocytosis. Lastly, TLR10 is expressed in humans, but the specific ligand for it remains to be elucidated.
Epithelial barrier

Apical side
- ZO-1
- ZO-2
- ZO-3
- Tight junction
- Aherens junction
- Gap junction
- Connexin
- Desmosome

Basal side
- Mucosal layer
- Periciliary layer
- Fibroblast
- Basal cell
- Goblet cell
- Pulmonary neuroendocrine cell
- Extracellular matrix

Inflammation mediators (IL-8, TNF-α, IL-6, GM-CSF)
- Antimicrobial peptides (defensins, cathelicidins)
- Chemotactic mediators (chemokines, leukotrienes)
- Interferons (IFN-α, IFN-β, IFN-γ)

Inhibition/clearance of bacteria & viruses

Recognition of microorganisms

Extracellular receptors
- RLRs
- NRLs

Cytosolic receptors
- TLR1
- TLR3
- TLR4
- TLR5
- TLR6
- TLR7
- TLR8
- TLR9

Inhibition/clearance of bacteria & viruses
the activation and expression of host cytokines, chemokines and antimicrobial peptides. TLRs are localized on immune and inflammatory cells; however, given that airway epithelial cells come into contact with several potential pathogens, the expression of TLRs is also relevant to immunity in the airways. Indeed, human bronchial epithelial cells express most TLRs; TLR2, TLR3, TLR5 and TLR6 being the most highly expressed.81

The PRR system can be also activated in response to allergens and viruses.82–84 PRRs within the epithelium are able to recognize allergen-associated danger signals via protease-dependent and protease-independent pathways. Protease-dependent pathways specifically require direct cleavage of cell-surface molecules or the activation of G-protein-coupled protease-activated receptors (PARs).85–88 RLRs are cytoplasmic receptors that recognize the presence of genomic RNA or double-stranded RNA viruses or double-stranded RNA intermediates from single-stranded RNA viruses. Melanoma differentiation-associated gene-5 is expressed in human bronchial epithelial cells, and is involved in the detection of rhinovirus and other viruses.89 NLRs are intracellular PRRs characterized by a central nucleotide-binding and oligomerization domain (NOD) and C-terminal leucine-rich repeats.90 More work is needed to define the role of NOD function in airway epithelial cells. Although the contribution of epithelial cells to antibacterial and antiviral immunity is well established, there is a paucity of information regarding the role of airway epithelial cells in immunity to fungi. CLRs belong to the dectin family and recognize fungal cell wall components. For example, Dectin-1 is expressed in airway epithelial cells, and is responsible for their activation by mycobacterium, Aspergillus and allergens such as house dust mite.91–95 Dectin receptors can be activated by β-glucans via TLR4 signalling, TLR2-dependent signalling, or induction of oxidative stress by intrinsic NADPH oxidase activity.94–96 Because fungal spores are potent allergens and are associated with allergic and chronic diseases of the respiratory tract such as asthma, the importance of the lung mycobiome should not be overlooked.97

**Respiratory infections and the initiation of epithelial immune response**

Infections play a crucial role in the induction and exacerbation of a multitude of chronic respiratory diseases such as asthma and COPD.98 Such infections represent a major cause of morbidity and mortality globally, and may involve bacteria (e.g. Streptococcus pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae) and viruses (e.g. RSV, influenza).99,100 The initiation of infection typically occurs through the exposure of the respiratory tract to bacterial cells or viral particles (Fig. 2).

During infection, viruses can bind to specific cellular receptors such as intracellular adhesion molecule 1 (ICAM-1) and sialic acid residues, whereas bacteria bind to platelet-activating factor (PAF) and mannose-6-phosphate (Man-6-P) receptors.101 The interaction between these infectious agents and the epithelial cells induces the stimulation of the PRRs, and the secretion of antimicrobial effector molecules, peptides, enzymes, reactive oxygen species together with a range of chemokines and growth factors. Collectively, these molecules facilitate the recruitment of inflammatory cells; however, given that airway epithelial cells come into contact with several potent pathogens, the expression of TLRs is also relevant to immunity in the airways.

In vivo, leakage of proteins such as albumin into the alveolar space has been reported following influenza infection.109 Viruses, pollutants and allergens are all associated with junction dysfunction and
exacerbated clinical symptoms across the spectrum of these diseases.\textsuperscript{103–105,110,111}

Defects in barrier structure and function have been observed in primary epithelial cell cultures from asthmatics even after being propagated for several weeks at air–liquid interface, suggesting that reduced barrier function is a stable property of these cells.\textsuperscript{112} The type 2 cytokines IL-4 and 13 induce barrier dysfunction by inhibiting expression of ZO-1, occludins, E-cadherin and β-catenin.\textsuperscript{113} It has been proposed that junctional disruption could be a T helper 2 (Th2) promoting signal in the airway to restore mucosal integrity.\textsuperscript{114} This idea is supported by the fact that siRNA knockdown of E-cadherin results in epidermal growth factor receptor (EGFR)-dependent production of Th2-promoting cytokines thymus- and activation-regulated chemokine (TARC) and thymic stromal lymphopoi etin (TSLP) by airway epithelial cells that explains the association between barrier dysfunction and Th2-driven pulmonary disease.\textsuperscript{115} If the wound healing response is not curtailed following restoration of mucosal integrity, detrimental airway remodelling can ensue. E-cadherin, in addition to having a structural role at adherens junctions, is also the ligand for CD103, which is expressed on innate and adaptive immune cells and a subset of dendritic cells. Furthermore, it also binds to KLRG1, which is expressed by natural killer cells and regulatory T-cells and group 2 innate lymphoid cells. E-cadherin and occludin are known to be downregulated in asthmatics,\textsuperscript{106,116,117} and the genes for E-cadherin and protocadherin-1 have been associated with airway hyperresponsiveness.\textsuperscript{118,119} E-cadherin anchors EGFR within adherens junctions,\textsuperscript{120} preventing activation of the receptor.\textsuperscript{121,122} EGFR can redistribute to the luminal surface of the cell as a result of reduced expression of E-cadherin culminating in activation.\textsuperscript{123} Excessive activation of EGFR can result in cell proliferation and goblet cell hyperplasia/metaplasia.\textsuperscript{124} Increased expression of EGFR has been observed in asthma and correlated with impaired mucosal barrier function.\textsuperscript{106}

When dissociated from E-cadherin, β-catenin can translocate to the nucleus, activating Wnt signalling, which results in cell proliferation.\textsuperscript{125} Dikkopf (DKK) proteins regulate Wnt signalling via interaction with Kremen (KRM) receptors,\textsuperscript{126} and the Wnt/β-catenin pathway has been implicated in IPF.\textsuperscript{127,128} DKK1 expression is increased in lung and bronchoalveolar lavage (BAL) fluid of IPF patients. In addition to being located in hyperplastic alveolar cells, the strongest expression is observed in basal bronchial epithelial cells. KRM1 expression is also elevated in the lung tissue of IPF patients, particularly in areas of bronchiolization.\textsuperscript{127} The phosphorylation signatures of β-catenin in IPF are the same as in normal lung development, again suggesting that repair of lung injury involves reactivation of developmental programmes.\textsuperscript{129} Wnt/β-catenin signalling is also implicated in the pathogenesis of COPD, but in direct contrast to what is observed in IPF, signalling in the mesenchymal compartment is inactivated rather than activated.\textsuperscript{130} Interestingly a shift from canonical Wnt signalling (β-catenin-dependent) to non-canonical pathways is suggested to drive pathology in IPF.\textsuperscript{131}

Basal cells, which are candidate stem cells in the conducting airways, are found in highest concentration in the trachea, and numbers diminish further down the bronchial tree to the bronchioles. Upon damage these cells upregulate p63, a basal cell-restricted transcription factor, which has been implicated in epithelial mesenchymal transition.\textsuperscript{132} It has been shown that basal epithelial cells overlying fibroblastic foci in IPF acquire increased reactivity, determined by p63 expression, and gain a partial mesenchymal phenotype,\textsuperscript{133} further evidence of the involvement of bronchial-derived cells in the pathogenesis of IPF.

Collectively, it is likely that the dialogue between specific bacterial communities and host is a dynamic phenomenon. The installation and location of the bacterial communities within the lungs is affected by the cellular components within the lungs as well as the abiotic environment (temperature, pH, mucus and pulmonary surfactant). Specifically, loss of barrier function can influence the composition of the respiratory microbiota by allowing the entry of pathogens and other particles. However, it is evident that more information is needed to elucidate the nature of the dialogue occurring between the respiratory microbiota and epithelial cells in the lungs to further understand the function and mechanisms through which the microbiota shapes immunity in the lung.

The gut–lung axis

An increasing number of studies have provided evidence of the cross-talk that occurs between the intestinal microbiota and the lungs, termed the ‘gut–lung axis’. Similar to the gut, the airway microbiota in healthy lungs is dominated by the short-chain fatty acid (SCFA)-producing bacteria: Bacteroidetes, Firmicutes and Proteobacteria. These are metabolically active bacteria that produce SCFAs via the bacterial fermentation of non-digestible carbohydrates by the gut microbiota; acetate, propionate and butyrate being the most abundant in the human intestinal tract.\textsuperscript{134} It is now well documented that the intestinal microbiota influences the microbial composition within the lung either by direct seeding of bacteria into the airways or by the distribution of SCFAs. These SCFAs not only act as a fuel for intestinal epithelial cells but also exert distinct physiological effects, acting as a link between the microbiota and the immune system, and playing a key role in maintaining mucosal immunity. Although there are limited studies investigating the impact of these SCFAs in the lungs, in the gut they have been shown to be integral for tightly formed and to promote anti-inflammatory mechanisms to sustain
The composition of a stable gut microbiota has been shown to have an influence on lung immunity. Mice devoid of their intestinal microbiota during early life are at an increased risk of developing allergic airway disease. An increased risk of asthma has been associated with a predominance of Bacteroides fragilis and total anaerobes in early life, decreases in the total abundances of Escherichia coli, Faecalibacterium, Lachnospira, Rothia and Veillonella bacterial genera. In adults, taxa-specific differences in the gut microbiota were observed, such as an increased relative abundance of Bifidobacterium adolescentis, which negatively correlated with the time since asthma diagnosis. Furthermore, mice fed a peptide-based enteral diet that increased the production of SCFAs attenuated elastase-induced inflammation and emphysema in the lung. The axis is by no means one-directional, with respiratory infection driving perturbations in the gut microbiome, but further work is needed to validate this. A study reported that the intranasal delivery of a non-absorbable tracer into the nasal cavity of mice appeared in the gastrointestinal tract shortly after. In addition, work by Sze et al. reported that intratracheal administration of lipopolysaccharide not only disrupted the airway microbiota but also led to the translocation of airway bacteria belonging to the Clostridium and Lachnospiraceae genera into the bloodstream and affected the gut microbiota within 24 hr, resulting in an evident increase in total bacterial load. Collectively, these studies provide evidence of the bidirectional communication happening between these two sites. However, our understanding of this cross-talk is still in its infancy, and there is a pressing need to uncover whether these changes observed in the microbiota are the cause or the effect of disease. Furthermore, there is growing evidence highlighting the use of oral antibiotics and their effect on lung immunity. Antibiotics could affect the gut microbiome and subsequently on lung immunity. To support this hypothesis, murine studies have shown that depletion of certain species within the gut microbiota due to antibiotic intake influences lung diseases and allergic inflammation. For example, microbial dysbiosis due to the use of macrolides in early life correlated with an increased risk of asthma in Finnish pre-school children. It is clear that we need to appreciate the interactions between the gut and airway microbiota in order to understand the impact of antibiotics on lung health.

Conclusions and future directions

The epithelial surfaces of the lung, including the proximal and distal airways, are now considered to play a pivotal role in maintenance of immune homeostasis. The epithelium acts as the first line of defence against inhaled viral, bacterial and fungal pathogens. Studies have shown that the epithelial surfaces of the human respiratory tract are colonized by a complex and dynamic microbiota that plays a role both in health and disease. It is becoming increasingly recognized that the cellular and physiological characteristics of the lungs impact the establishment and persistence of these bacterial communities. Dysregulation of the epithelial immune response and barrier function along with microbial dysbiosis can contribute to chronic inflammatory lung diseases such as asthma, COPD, CF and IPF. However, the precise nature of the relationship between the respiratory microbiome and the epithelium in the lungs remains an active area of investigation. A better understanding of this interaction in maintaining airway homeostasis will provide new insights into the pathogenesis of several respiratory conditions as well as novel diagnostic and therapeutic opportunities. Emerging evidence, particularly involving SCFAs, has highlighted a link between the gut and the lung and the microbial communities within. These results highlight the need for future studies that will characterize the microbiota and metabolites comprising these two mucosal sites and determine their interaction with the host in order to develop more targeted treatments for lung diseases.

Disclosures

The authors have no competing interests or conflicts of interest to declare.

References

1. Hiemstra PS, McCray PB Jr, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J 2015; 45:1150–62.
2. Weibel ER. Morphometry of the Human Lung. Berlin Heidelberg: Springer, 1963.
3. Leiva-Juarez MM, Kolls JK, Evans SE. Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol 2018; 11:21–34.
4. Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis Model Mech 2010; 3:545–56.
REVIEW SERIES: BARRIER IMMUNITY

R. Invernizzi et al.
Lung microbiome epithelial interaction

63 Schutte BC, McCray PB Jr. [beta]-defensins in lung host defense. Am Rev Respir Physiol 2002; 64:709–48.
64 Malla P, Webber J, Gill SK, Trujillo-Torralbo MB, Calderazzo MA, Finney L et al. Role of airway glycol in bacterial infections in patients with chronic obstructive pulmonary disease. J Clin Immunol 2009; 29:795–805.
65 O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity and the pathogenesis of chronic lung disease. J Immunol 2016; 196:4839–47.
66 Maitihasan S, Monack DM. Inflammamae and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007; 7:531–40.
67 Ye Z, Ting JP. NLRC5: the nucleus-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 2008; 20:8–9.
68 Medhihotri R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449:819–26.
69 Takeuchi O, Akira S. Pattern recognition receptors and inflammasomes. Cell 2010; 140:805–20.
70 Takeda K, Kaisho T. Toll-like receptors. Annu Rev Immunol 2003; 21:335–76.
71 Hemmi H, Takeuchi O, Kawai T, Sato S, Sanjo H et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740–45.
72 Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196–200.
73 Alexander K, Loh AC, Medhihotri R, Favello RA. Recognition of double-stranded RNA by RIG-I-like receptors and activation of NF-kappaB by Toll-like receptor 3. Nature 2003; 421:473–82.
74 Hayashi F, Smith KD, Oszinsky A, Hawn TR, Yi EC, Goodlett DR et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099–103.
75 de Bouteiller O, Merck E, Hasana U, Hubac S, Bengasui B, Trinchieri G et al. Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem 2005; 280:138–43.
76 Latz E, Scheneweyer A, Visentin A, Fitzgerald KA, Monks BG, Ketterer CF et al. TLR9 signals after translocation from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190–5.
77 Lee J, Chong TH, Rudecke V, She L, Pitha PM, Cason DA et al. Molecular basis for the immunomodulatory activity of guanosine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2005; 102:6646–51.
78 Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shigeta M, Seto Y et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3315–22.
79 Nishiya T, DeFranco AL. Lipid-anchored regulatory receptor interaction pattern reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J Biol Chem 2004; 279:18008–17.
80 Oosting M, Cheng BC, Boulanger JM, Vestering-Stenger P, Plantinga TS, Verschueren IC et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci USA 2014; 111:E4478–84.
81 Sha Q, Truong-Tran AQ, Platt JR, Beck LA, Schirmmer RP. Activation of airway epithelial cells by Toll-like receptor agonists. Am J Respir Cell Mol Biol 2004; 31:358–64.
82 Hammad H, Chiappe M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. J Immunol 2005; 174:2482–86.
83 Hammad H, Takeuchi O, Kaisho T, Sanjo H, Hoshino K et al. Toll-like receptor 7 is required for the interaction of lipopolysaccharide with macrophages. J Immunol 2001; 167:731–40.
84 Rasmussen P, Zhang J, Wang J, Zhao Y, Guevarra DC, Hershenson MB et al. Rhinovirus-induced barrier dysfunction in polarized airway epithelial cells. J Am Respir Crit Care Med 2008; 178:1271–81.
85 Comstock AT, Ganasan S, Chatteraj A, Farias AN, Margolis BL, Hershenson MB et al. Rhinovirus-induced barrier dysfunction in polarized airway epithelial cells is mediated by NADPH oxidase 1. J Virol 2011; 85:6793–80.
86 Rezaee F, Delando SA, Ivanov AI, Chapman TJ, Knodden SA, Beck LA et al. Sustained protein kinase D activation mediates respiratory syncytial virus-induced airway barrier disruption. J Virol 2013; 87:1088–95.
87 Xiao C, Paddickombe SM, Field S, Haywood J, Broughton-Hadsh P, Puxeddu I et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128:549–56.e12.
88 Hackett TL, De Bruin HG, Shaefer F, van den Berge M, van Oosterhout AJ, Postma DS et al. Carveol-1 controls epithelial barrier function. Implications for asthma. Am J Respir Cell Mol Biol 2013; 49:662–71.
89 Skhiri R, Otaki F, Bouna P, Dang DT, Tetreau M, Strulovic-Band Y et al. Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo. Cell Mol Life Sci 2011; 68:877–92.
90 Lehnert EB, Swan ZD, Bussel SJ, Hartman AL, Caryn JP, O’Malley KJ et al. Widespread virus replication in alveoli drives acute respiratory distress syndrome in aerosolized H9N2 influenza infection of mice. J Immunol 2017; 198:1816–26.
91 Coyne CB, Shen L, Turner JR, Bergehson JM. Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab6 and Rab5. Cell Host Microbe 2007; 1:218–21.
92 Molynieux PL, Maillo P, Cox MJ, Footitt J, Willis-Owen SA, Homola D et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:1224–31.
93 Grainge C, Dennison P, Lau L, Davies D, Howarth P. Asthmatic and normal respiratory epithelial cells respond differently to mechanical apical stress. Am J Respir Crit Care Med 2014; 190:477–80.
94 Saatian B, Rezaee F, Desando S, Emo J, Chapman T, Knodden S et al. Interleukin-13 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers 2013; 1:e24333.
95 Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 2013; 13:607–14.
96 Heijink DH, Kies PM, Kaufman HF, Postma DS, van Oosterhout AJ, Yellenga E. Down-regulation of E-cadherin in human bronchial epithelial cells leads to epidermal growth factor receptor-dependent Th2 cell-promoting activity. J Immunol 2007; 178:7678–85.
